CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections - Wikidata - wikimedia - TriplyDB

CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections

CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections

http://www.wikidata.org/entity/Q35270714

about

Conformational analysis, molecular structure and solid state simulation of the antiviral drug acyclovir (zovirax) using density functional theory methods.A cutting-edge view on the current state of antiviral drug development.Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase.Update on emerging antivirals for the management of herpes simplex virus infections: a patenting perspective.Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes Progress in the development of new therapies for herpesvirus infections TAOK3 phosphorylates the methylenecyclopropane nucleoside MBX 2168 to its monophosphate.Herpes Simplex Encephalitis: Lack of Clinical Benefit of Long-term Valacyclovir Therapy A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency.Management of multidrug-resistant viruses in the immunocompromised host.Molecular diagnosis and management of viral infections in hematopoietic stem cell transplant recipients.Design and development of antivirals and intervention strategies against human herpesviruses using high-throughput approach.Helicase-primase as a target of new therapies for herpes simplex virus infections.Comparison of three dimensional synergistic analyses of percentage versus logarithmic data in antiviral studies.Herpes Simplex Encephalitis: an Update.Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation.Treatment of BK virus-associated nephropathy with CMX001 after kidney transplantation in a young child.Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis.Editorial Commentary: Failure of Adjunctive Valacyclovir to Improve Outcomes in Herpes Simplex Encephalitis.Design, Synthesis, and Biological Evaluation of γ-Aminopropyl Silatrane-Acyclovir Hybrids with Immunomodulatory Effects.

P2860

Q33833712-116234EA-31DF-4235-BA20-626E713426DA Q34036018-94C233AE-26A7-435B-B55D-D11458CF83D8 Q35270303-A6B9ADDA-4A11-4A40-BF9B-C0DFDC83AA91 Q35531731-09D6F94A-96D8-49BF-8D39-22418CA2CCDE Q35559725-2C97032F-91A3-4970-B6E7-FE71621E41F1 Q35590695-A1B89109-BE0F-4F21-B9BC-177E56DFA528 Q35638861-C7096E0B-AD04-40EF-8159-80D2CE87252E Q35975455-66BD2A17-5488-45D6-8313-F3AD3D90D2D2 Q36591414-DD393039-C99B-49FD-8D69-DF07B14181F9 Q37970424-38AF3C80-0BBE-40F2-9E4C-91AB4600FD09 Q38002109-3AD11F56-916A-4514-A76B-40ECC6CC1E0B Q38227257-9F642688-B80E-4D68-A40D-CE13FAEBDA13 Q38351481-848DC443-BCD1-49FD-902E-5DF90E0DD35D Q38694084-1F668E34-19AB-4718-B251-23F660A6EC2B Q38934303-1E4C84FA-3E6D-4E90-ABDB-778F8C1C7EAE Q40591596-E18AB1DB-1A5D-422C-9BA9-EADD24EED3A3 Q42195428-B8F3007A-C82F-494B-9ACB-8B80A60AE8C4 Q45325171-2502E2C0-D064-49A0-A210-39B8B3666EDD Q51022297-ABF235CC-5392-4114-9955-C9DC708BCAB7 Q51066899-C6F02C15-2D24-4A04-A7E5-92EE20EE94E8

P2860

CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections

http://www.wikidata.org/entity/Q35270714

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections

@ast

CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections

@en

type

label

CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections

@ast

CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections

@en

prefLabel

CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections

@ast

CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections

@en

P1433

Q35270714-8F996C4C-E45E-426A-911A-91E414D6D69E

P1476

Q35270714-E612BD67-5954-4D7B-A872-CC54AA9AB261

P2093

Q35270714-0846823B-1360-4CEA-A82F-BF73590B9B9D

Q35270714-5161931B-271B-4224-9BBD-1252BA219428

Q35270714-67485D32-E825-4E19-A106-B3492B01C4C0

Q35270714-9BC14AC4-59BC-481C-9907-B0AD38C66962

Q35270714-FB485686-467C-463E-B478-639AF2BC1CF6

P2860

Q35270714-0AEE4972-C3A2-4A1E-9EFB-2C16FFDE6316

Q35270714-13E773D4-0713-4074-B378-BF26BC225202

Q35270714-1F8D3A16-1A2B-48F6-9F31-16D5D57D3E07

Q35270714-20F5B836-D1A1-432E-88AE-9AD7B79551B2

Q35270714-26DFDE85-C320-4B1C-8D4C-9879AF4A59BF

Q35270714-27CA775E-95E5-42C7-9D06-5A0BB8729CDC

Q35270714-27D7EEE5-4D5D-43A8-8378-FDBBE4A89884

Q35270714-330A7EB2-A9DA-400F-89CE-A2FACEEBC355

Q35270714-3485870E-7B88-45C7-871A-A72740DEAE23

Q35270714-373E5970-340D-4B25-8179-665C479613E9

P304

Q35270714-0E44834A-0887-460F-A0D1-3F888BEF49F7

P31

Q35270714-10180DE6-D9C5-40A3-864F-54B2EBDDEDFE

P356

Q35270714-F1A74331-9C7C-44D1-B467-B6E7D85F850C

P407

Q35270714-985E4CB0-D148-4826-B52C-22F171D5F666

P433

Q35270714-775BF78E-32CF-4C67-BD1E-3D458B68CD38

P478

Q35270714-3E5FDDFA-BCF9-4AA9-AF97-4DEA78258055

P577

Q35270714-9D2DADB5-6E0E-46AD-9679-B7A8FC9F3636

P5875

Q35270714-AE1BF9B2-79AD-4ECB-9DB2-82D8B03E8562

P698

Q35270714-862A15C4-6226-4365-BB7F-2EDDD89AE5A7

P932

Q35270714-83DE66DB-C5CD-4006-8600-AFF789A986D3

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections

@en

P2093

Caroll B Hartline

http://www.w3.org/2001/XMLSchema#string

Debra C Quenelle

http://www.w3.org/2001/XMLSchema#string

E Randall Lanier

http://www.w3.org/2001/XMLSchema#string

Earl R Kern

http://www.w3.org/2001/XMLSchema#string

Mark N Prichard

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and Efficacy of High-Dose Intravenous Acyclovir in the Management of Neonatal Herpes Simplex Virus Infections

The probability of in vivo reactivation of herpes simplex virus type 1 increases with the number of latently infected neurons in the ganglia.

Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies

Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency

Persistence of herpes simplex virus DNA in cerebrospinal fluid of neonates with herpes simplex virus encephalitis.

Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function

The latent herpes simplex virus type 1 genome copy number in individual neurons is virus strain specific and correlates with reactivation

Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro.

Current recommendations for the treatment of genital herpes.

Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

P304

4728-4734

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00545-11

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51520530

http://www.w3.org/2001/XMLSchema#string

P698

21788472

http://www.w3.org/2001/XMLSchema#string

P932

3186990

http://www.w3.org/2001/XMLSchema#string